LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
LIVERFASt outperforms FIB-4, in sequential combination with VCTE, for identifying ≥F3 stages in MASLD including T2DM
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Combination of LF and LSM using Fibroscan outperforms FIB-4 and LSM in patients with T2D
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter
Combination of LIVERSTAT and Fibroscan-LSM outperforms FIB-4 and LSM for MASLD Advanced Fibrosis (F3F4) — multicenter
Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)
Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)
Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort)
Comparative Performances of LIVERFASt, Fibroscan and other NITs for severe fibrosis in NAFLD patients (Bordeaux cohort)
Long-term prognosis of MAFLD patients according to non-invasive methods
Long-term prognosis of MAFLD patients according to non-invasive methods
Noninvasive LIVERFASt transition rate to liver fibrosis, similar to liver biopsy in NAFLD patients
Noninvasive LIVERFASt transition rate to liver fibrosis, similar to liver biopsy in NAFLD patients
Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome
Application of LIVERFASt to predict steatosis in Chronic Hepatitis B patients with metabolic syndrome